-
In this Issue: Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
-
Ask the next patient who comes in your office, "What is the most effective reversible contraceptive?" How many of them will name the intrauterine device (IUD)?
-
Review your patient charts for the past month. If national statistics are any indication, chances are many of those cases include a diagnosis of urinary tract infection (UTI).
-
Use of the cervical cancer vaccine may soon expand: Merck has filed with the Food and Drug Administration (FDA) for use of Gardasil (Merck & Co.; Whitehouse Station, NJ) in use in women ages 27 through 45.
-
Your next patient is a healthy, fit 45-year-old nonsmoking woman. She says her menstrual periods are now less regular, and she reports having intermittent hot flashes. Newly divorced, she is now sexually active and wonders which contraceptive is right for her. What's your recommendation?
-
While women now have more contraceptive options, many still struggle with achieving success with their chosen contraceptive method. What can clinicians do to improve method success?
-
The American Public Health Association (APHA) has just issued a policy statement calling for schools of public health, pharmacy, and medicine to include specific education around the adverse impact of douching on reproductive and maternal outcomes.
-
Looking at CAD through the PERISCOPE; Addressing Agitation and Aggression in Persons with Advanced Dementia; It Used To Be Easier To Treat Sinusitis; CAC: A kinder, Gentler Way to Predict Cardiovascular Risk; Was Mae West Right? CV Risk Reduction: Too Much of A Good Thing is Wonderful; Midlife Contraception
-
Clinicians are becoming more attuned to the many complications of influenza, particularly with the high morbidity and mortality seen with H5N1 strains spreading around the world.
